The Ronald O. Perelman Department of Dermatology, NYU Langone Health, New York, New York.
JAMA Dermatol. 2023 Feb 1;159(2):160-171. doi: 10.1001/jamadermatol.2022.5508.
Primary cutaneous squamous cell carcinoma is usually curable; however, a subset of patients develops poor outcomes, including local recurrence, nodal metastasis, distant metastasis, and disease-specific death.
To evaluate all evidence-based reports of patient risk factors and tumor characteristics associated with poor outcomes in primary cutaneous squamous cell carcinoma and to identify treatment modalities that minimize poor outcomes.
PubMed, Embase, and SCOPUS databases were searched for studies of the topic in humans, published in the English language, from database inception through February 8, 2022.
Two authors independently screened the identified articles and included those that were original research with a sample size of 10 patients or more and that assessed risk factors and/or treatment modalities associated with poor outcomes among patients with primary cutaneous squamous cell carcinoma.
Data extraction was performed by a single author, per international guidelines. The search terms, study objectives, and protocol methods were defined before study initiation. A total of 310 studies were included for full-text assessment. Owing to heterogeneity of the included studies, a random-effects model was used. Data analyses were performed from May 25 to September 15, 2022.
For studies of risk factors, risk ratios and incidence proportions; and for treatment studies, incidence proportions.
In all, 129 studies and a total of 137 449 patients with primary cutaneous squamous cell carcinoma and 126 553 tumors were included in the meta-analysis. Several patient risk factors and tumor characteristics were associated with local recurrence, nodal metastasis, distant metastasis, disease-specific death, and all-cause death were identified. Among all factors reported by more than 1 study, the highest risks for local recurrence and disease-specific death were associated with tumor invasion beyond subcutaneous fat (risk ratio, 9.1 [95% CI, 2.8-29.2] and 10.4 [95% CI, 3.0- 36.3], respectively), and the highest risk of any metastasis was associated with perineural invasion (risk ratio, 5.0; 95% CI, 2.3-11.1). Patients who received Mohs micrographic surgery had the lowest incidence of nearly all poor outcomes; however, in some results, the 95% CIs overlapped with those of other treatment modalities.
This meta-analysis identified the prognostic value of several risk factors and the effectiveness of the available treatment modalities. These findings carry important implications for the prognostication, workup, treatment, and follow-up of patients with primary cutaneous squamous cell carcinoma.
PROSPERO Identifier: CRD42022311250.
原发性皮肤鳞状细胞癌通常是可治愈的;然而,一部分患者会出现不良预后,包括局部复发、淋巴结转移、远处转移和疾病特异性死亡。
评估所有与原发性皮肤鳞状细胞癌不良预后相关的基于证据的患者风险因素和肿瘤特征的报告,并确定能最大限度减少不良预后的治疗方法。
在人类研究中,从数据库建立到 2022 年 2 月 8 日,通过 PubMed、Embase 和 SCOPUS 数据库搜索了关于该主题的所有英文发表的基于证据的报告。
两位作者独立筛选了确定的文章,并纳入了样本量为 10 例或更多且评估了原发性皮肤鳞状细胞癌患者不良预后相关风险因素和/或治疗方法的原始研究。
根据国际指南,由一位作者进行数据提取。在研究开始前,定义了搜索词、研究目标和方案方法。共有 310 项研究被纳入全文评估。由于纳入研究的异质性,使用了随机效应模型。数据分析于 2022 年 5 月 25 日至 9 月 15 日进行。
对于风险因素研究,使用风险比和发病率比例;对于治疗研究,使用发病率比例。
总共纳入了 129 项研究和总共 137449 例原发性皮肤鳞状细胞癌患者和 126553 例肿瘤的meta 分析。确定了几个与局部复发、淋巴结转移、远处转移、疾病特异性死亡和全因死亡相关的患者风险因素和肿瘤特征。在所有报告超过 1 项研究的因素中,与肿瘤侵犯皮下脂肪有关的局部复发和疾病特异性死亡的风险最高(风险比,9.1[95%CI,2.8-29.2]和 10.4[95%CI,3.0-36.3]),与任何转移相关的最高风险与神经周围侵犯有关(风险比,5.0;95%CI,2.3-11.1)。接受 Mohs 显微外科手术的患者几乎所有不良预后的发生率最低;然而,在某些结果中,95%CI 与其他治疗方法的 95%CI 重叠。
这项 meta 分析确定了几个风险因素的预后价值和现有治疗方法的有效性。这些发现对原发性皮肤鳞状细胞癌患者的预后、检查、治疗和随访具有重要意义。
PROSPERO 标识符:CRD42022311250。